IgA antibodies against the Epstein‐Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients
Authors:
- 23 June 2009
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 81 (8) , 1412-1421
Abstract
Serological tests for Epstein‐Barr virus (EBV) have been used for many years as diagnostic predictors of nasopharyngeal carcinoma. It has been shown previously that the conventional immunofluorescence assay has a limited diagnostic value, especially in young patients from North African area. In the search for more reliable immunoglobulin (Ig) G or IgA antibody markers for the diagnosis of nasopharyngeal carcinoma, immunoblot analysis was performed using a full spectrum of EBV proteins. Sera were collected from 108 patients with nasopharyngeal carcinoma and three control groups composed of 18 patients with lymphoma, 18 other patients with autoimmune diseases and 55 healthy EBV carriers. It was observed that the IgA Epstein‐Barr nuclear antigen 1 (EBNA1), IgA early antigen (EA)‐p138 and IgG EA‐p138 antibodies represent the most specific anti‐EBV responses in either young or older patients with nasopharyngeal carcinoma which yield higher positive rates compared to the three control groups. Since the IgA EBNA1 response showed the highest sensitivity value for the detection of nasopharyngeal carcinoma, a novel enzyme‐linked immunosorbent assay (ELISA) was established using a GST‐EBNA1 protein expressed in bacteria, containing the P‐threonine EBNA1 subtype cloned from DNA EBV sequence of C15 xenograft cells. Detection rates were 85.7% and 94.9% in young and older patients with nasopharyngeal carcinoma respectively, while only 3.6%, 11.1%, and 16.6% in healthy EBV carriers, patients with lymphoma and patients with autoimmune diseases, respectively. Thus, IgA EBNA1 ELISA may be useful for early diagnosis and mass screening of nasopharyngeal carcinoma in Tunisia even in young patients. J. Med. Virol. 81:1412–1421, 2009.Keywords
This publication has 33 references indexed in Scilit:
- Prognostic factors in metastatic nasopharyngeal carcinomaCancer/Radiothérapie, 2007
- Analyses of the prognostic significance of the Epstein–Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinomaJournal of Clinical Virology, 2007
- Native early antigen of Epstein–Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinomaJournal of Medical Virology, 2007
- Expression of VCA (viral capsid antigen) and EBNA1 (Epstein–Barr‐virus‐encoded nuclear antigen 1) genes of Epstein–Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinomaBiotechnology and Applied Biochemistry, 2007
- Single-Assay Combination of Epstein-Barr Virus (EBV) EBNA1- and Viral Capsid Antigen-p18-Derived Synthetic Peptides for Measuring Anti-EBV Immunoglobulin G (IgG) and IgA Antibody Levels in Sera from Nasopharyngeal Carcinoma Patients: Options for Field ScreeningJournal of Clinical Microbiology, 2006
- Antibody Responses to Recombinant Epstein-Barr Virus Antigens in Nasopharyngeal Carcinoma Patients: Complementary Test of ZEBRA Protein and Early Antigens p54 and p138Journal of Clinical Microbiology, 2001
- Restricted Low‐Level Human Antibody Responses against Epstein‐Barr Virus (EBV)–Encoded Latent Membrane Protein 1 in a Subgroup of Patients with EBV‐Associated DiseasesThe Journal of Infectious Diseases, 1999
- Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein‐Barr virus capsid antigen complexJournal of Medical Virology, 1993
- Serum and salivary IgA antibodies against a defined epitope of the Epstein‐Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinomaInternational Journal of Cancer, 1990
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976